
Sign up to save your podcasts
Or
How do you counsel patients eligible for the RSV vaccines? What do the results of the RENOIR and AReSVi trials tell us and how do they compare? How should we interpret vaccine trials in the first place? Tune in to the fourth episode of Beyond Journal Club, a new series brought to you by Core IM in collaboration with NEJM Group.
Sponsor: Pathway FREE evidence-based clinical decision support app. Guideline summaries, interactive algorithms, landmark trials & more
Show Notes & Transcript
Time Stamps:
(02:30) | Epidemiology of RSV
(03:46) | Development of RSV vaccine
(05:55) | Vaccine trial design
(12:22) | ARESVI and RENOIR Trials
(18:18) | Who should we recommend the RSV vaccine to?
(19:50) | What don’t we know?
Tags: IMCore, CoreIM, primary care, infectious disease, nurse practitioner, pharmacist, physician assistant
4.8
10521,052 ratings
How do you counsel patients eligible for the RSV vaccines? What do the results of the RENOIR and AReSVi trials tell us and how do they compare? How should we interpret vaccine trials in the first place? Tune in to the fourth episode of Beyond Journal Club, a new series brought to you by Core IM in collaboration with NEJM Group.
Sponsor: Pathway FREE evidence-based clinical decision support app. Guideline summaries, interactive algorithms, landmark trials & more
Show Notes & Transcript
Time Stamps:
(02:30) | Epidemiology of RSV
(03:46) | Development of RSV vaccine
(05:55) | Vaccine trial design
(12:22) | ARESVI and RENOIR Trials
(18:18) | Who should we recommend the RSV vaccine to?
(19:50) | What don’t we know?
Tags: IMCore, CoreIM, primary care, infectious disease, nurse practitioner, pharmacist, physician assistant
324 Listeners
247 Listeners
492 Listeners
703 Listeners
277 Listeners
3,330 Listeners
185 Listeners
694 Listeners
515 Listeners
349 Listeners
248 Listeners
426 Listeners
366 Listeners
285 Listeners
219 Listeners